[1]薛　红,刘一村,程苕莼,等.瘦型与肥胖型代谢相关脂肪性肝病患者的临床特征比较[J].新乡医学院学报,2022,39(8):731-734.[doi:10.7683/xxyxyxb.2022.08.006]
　XUE Hong,LIU Yicun,CHEN Tiaochun,et al.Comparison of clinical characteristics of lean and obese patients with metabolic associated fatty liver disease[J].Journal of Xinxiang Medical University,2022,39(8):731-734.[doi:10.7683/xxyxyxb.2022.08.006]
点击复制

瘦型与肥胖型代谢相关脂肪性肝病患者的临床特征比较
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年8
页码:
731-734
栏目:
临床研究
出版日期:
2022-08-05

文章信息/Info

Title:
Comparison of clinical characteristics of lean and obese patients with metabolic associated fatty liver disease
作者:
薛　红1; 刘一村2; 程苕莼2; 田李均3; 邵建国4; 卞兆连4
（1.南通大学附属南通第三医院/南通市第三人民医院感染科，江苏　南通　226006;2.南通大学医学院，江苏　南通　226006;3.南通大学附属南通第三医院/南通市第三人民医院重症医学科，江苏　南通　226006;4.南通大学附属南通第三医院/南通市第三人民医院消化科,江苏　 南通　226006）
Author(s):
XUE Hong1; LIU Yicun2; CHEN Tiaochun2; TIAN Lijun3; SHAO Jianguo4; BIAN Zhaolian4
(1.Department of Infectious Disease，the Third Hospital of Nantong Affiliated to Nantong University，Nantong 226006，Jiangsu Province，China;2.Medical School of Nantong University，Nantong 226006，Jiangsu Province，China;3.Department of Critical Care Medicine，the Third Hospital of Nantong Affiliated to Nantong University，Nantong 226006，Jiangsu Province，China;4.Department of Gastroenterology,the Third Hospital of Nantong Affiliated to Nantong University，Nantong 226006，Jiangsu Province，China)
关键词:
代谢相关脂肪性肝病; 瘦型; 肥胖; 临床特征
Keywords:
metabolic associated fatty liver disease; lean:obesity:clinical features
分类号:
R575
DOI:
10.7683/xxyxyxb.2022.08.006
文献标志码:
A
摘要:
目的　比较瘦型与肥胖型代谢相关脂肪性肝病（MAFLD）患者的临床特征。方法　选择2019年6月至2020年12月南通市第三人民医院收治的198例MAFLD患者为研究对象，根据体质量指数（BMI）将患者分为瘦型MAFLD组(n=42)和肥胖型MAFLD组(n=156)，收集2组患者的临床资料，对2组患者的临床资料进行比较。结果　瘦型MAFLD组患者男性所占比例显著高于肥胖型MAFLD组，年龄、BMI、游离三碘甲状腺原氨酸显著低于肥胖型MAFLD组，白蛋白、尿酸、总胆固醇显著高于肥胖型MAFLD组（P<0.05）；其余指标2组间比较差异无统计学意义（P>0.05）。瘦型MAFLD组中合并高血压、冠状动脉性心脏病、空腹血糖受损/糖尿病、高尿酸血症、甲状腺功能减退患者的比例均显著高于肥胖型MAFLD组（P<0.05）；2组中合并高胆固醇血症、高三酰甘油血症患者的比例比较差异无统计学意义（P>0.05）。瘦型MAFLD组患者肝脏硬度值显著低于肥胖型MAFLD组 (P<0.05)；2组患者的肝脏脂肪衰减参数比较差异无统计学意义(P>0.05)。 结论　与肥胖型MAFLD患者相比，瘦型MAFLD患者中男性比例更高，患者年龄更轻，合并高血压、糖尿病、甲状腺功能减退等代谢相关并发症概率更高。
Abstract:
Objective　To compare the clinical characteristics of lean and obese patients with metabolic associated fatty liver disease(MALFD).Methods　A total of 198 patients with MALFD admitted to the Third People′s Hospital of Nantong from June 2019 to December 2020 were selected as the research objects.The patients were divided into lean MALFD group (n=42) and obese MALFD group (n=156) according to the body mass index（BMI）.The clinical data of patients in the two groups were collected and compared.Results　The proportion of male patients in the lean MALFD group was significantly higher than that in the obese MALFD group (P<0.05);the age,BMI and free triiodothyronine of patients in the lean MALFD group were significantly lower than those in the obese MALFD group (P<0.05);the levels of albumin,uric acid and total cholesterol of patients in the lean MALFD group were significantly higher than those in the obese MALFD group (P<0.05);there was no significant difference in other indexes of patients between the two groups (P>0.05).The proportion of patients with hypertension,coronary heart disease,impaired fasting glucose/diabetes,hyperuricemia and hypothyroidism in the lean MAFLD group were significantly higher than those in the obese MAFLD group (P<0.05);there was no significant difference in the proportion of patients with hypercholesterolemia and hypertriglyceridemia between the two groups (P>0.05).The liver stiffness measurement of patients in the lean MALFD group was significantly lower than that in the obese MALFD group (P<0.05)；there was no significant difference in controlled attenuation parameter of patients between the two groups (P>0.05).Conclusion　　Compared with obese MAFLD patients,the proportion of male patients in lean MAFLD patients is higher,the age is younger,and the probability of patients with metabolic complications such as hypertension,diabetes and hypothyroidism are higher.

参考文献/References:

［1］　FAN J G,KIM S U,WONG V W.New trends on obesity and NAFLD in Asia［J］.J Hepatol,2017,67(4):862-873.
［2］　ABENAVOLI L,MILIC N,DI RENZO L,et al.Metabolic aspects of adult patients with nonalcoholic fatty liver disease ［J］.World J Gastroenterol,2016,22(31):7006-7016.
［3］　ESLAM M,NEWSOME P N,SARIN S K,et al.A new definition for metabolic dysfunction-associated fatty liver disease:an international expert co nsensus statement ［J］.J Hepatol,2020,73(1):202-209.
［4］　黄磊杰,许炎煌,范建高.重视非酒精性脂肪性肝病异质性的临床研究［J］.中华肝脏病杂志,2020,28(3):193-197.
HUANG L J,XU Y H,FAN J G.Emphasis on clinical study of heterogeneity of non-alcoholic fatty liver disease［J］.Chin J Hepatol,2020,28(3):193-197.
［5］　POLYZOS S A,KOUNTOURAS J,MANTZOROS C S.Obesity and nonalcoholic fatty liver disease:from pathophysiology to therapeutics［J］.Metabolism,2019,92:82-97.
［6］　HAGSTROM H,NASR P,EKSTEDT M,et al.Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease:a long-term follow-up study［J］.Hepatol Commun,2018,2:48-57.
［7］　薛芮,范建高.代谢相关脂肪性肝病新定义的国际专家共识简介［J］.临床肝胆病杂志,2020,36(6):1224-1227.
XUE R,FAN J G.Brief introduction of an international expert consensus statement:a new definition of metabolic associated fatty liver disease［J］.J Clin Hepatol,2020,36(6):1224-1227.
［8］　ZENG J,YANG R X,SUN C,et al.Prevalence,clinical characteristics,risk factors,and indicators for lean Chinese adults with nonal coholic fatty liver disease［J］.World J Gastroenterol,2020,26(15):1792-1804.
［9］　THE LANCET GASTROENTEROLOGYH.Redefining non-alcoholic fatty liver disease:what′s in a name［J］.Lancet Gastroenterol Hepatol,2020,5(5):419.
［10］　STEFAN N,SCHICK F,HRING H U.Causes,characteristics,and consequences of metabolically unhealthy normal weight in humans［J］.Cell Metab,2017,26(2):292-300.
［11］　YOUNOSSI Z,ANSTEE Q M,MARIETTI M,et al.Global burden of NAFLD and NASH:trends,predictions,risk factors and prevention［J］.Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.
［12］　YE Q,ZOU B,YEO Y H,et al.Global prevalence,incidence,and outcomes of non-obese or lean non-alcoholic fatty liver disease:a systematic review and meta-analysis［J］.Lancet Gastroenterol Hepatol,2020,5(8):739-752.
［13］　YOUNG S,TARIQ R,PROVENZA J,et al.Prevalence and profile of nonalcoholic fatty liver disease in lean adults:systematic review and meta-analysis［J］.Hepatol Commun,2020,4(7):953-972.
［14］　LU F B,ZHENG K I,RIOS R S,et al.Global epidemiology of lean non-alcoholic fatty liver disease:a systematic review and meta-analysis［J］.J Gastroenterol Hepatol,2020,35(12):2041-2050.
［15］　CHEN Y L,LI H,LI S,et al.Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China:a cross-sectional comparative study［J］.BMC Gastroenterol,2021,21(1):212.
［16］　LIN S,HUANG J,WANG M,et al.Comparison of MAFLD and NAFLD diagnostic criteria in real world ［J］.Liver Int,2020,40(9):2082-2089.
［17］　KIM S H,PARK H Y,LEE H S,et al.Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity ［J］.Scientific Reports,2020,10(1):1025.
［18］　申利敏.肝脏瞬时弹性成像技术在肝硬化患者治疗随访中的应用研究［J］.河南医学研究,2017,26(2):274-275.
SHEN L M.Application of transient elastography in the follow-up of patients with liver cirrhosis［J］.Henan Med Res,2017,26(2):274-275.
［19］　SOOKOIAN S,PIROLA C J.Systematic review with meta-analysis:the significance of histological disease severity in lean patie nts with nonalcoholic fatty liver disease［J］.Aliment Pharmacol Ther,2018,47(1):16-25.
［20］　REN T Y,FAN J G.What are the clinical settings and outcomes of lean NAFLD［J］.Nat Rev Dis Primers,2021,18(5):289-90.

相似文献/References:

[1]张莉莉,翁孝刚,姚姝帆.血糖波动与2型糖尿病合并代谢相关脂肪性肝病的相关性[J].新乡医学院学报,2023,40(5):427.[doi:10.7683/xxyxyxb.2023.05.005]
　ZHANG Lili,WENG Xiaogang,YAO Shufan.Relationship between glycemic variability and type 2 diabetes mellitus combined with metabolic associated fatty liver disease[J].Journal of Xinxiang Medical University,2023,40(8):427.[doi:10.7683/xxyxyxb.2023.05.005]

更新日期/Last Update: 2022-08-23